FY2025 EPS Estimates for ATXS Lowered by Cantor Fitzgerald

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Equities researchers at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Astria Therapeutics in a report released on Thursday, November 13th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biotechnology company will earn ($2.26) per share for the year, down from their prior estimate of ($2.04). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2026 earnings at ($2.25) EPS.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.14). The company had revenue of $0.71 million during the quarter, compared to analysts’ expectations of $10.67 million.

ATXS has been the topic of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Astria Therapeutics in a report on Wednesday, October 8th. Evercore ISI reiterated an “outperform” rating and issued a $26.00 price target on shares of Astria Therapeutics in a report on Wednesday, October 1st. HC Wainwright cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 16th. JMP Securities reissued a “market perform” rating on shares of Astria Therapeutics in a report on Wednesday, October 15th. Finally, Jefferies Financial Group lowered Astria Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $30.00 to $13.00 in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $24.50.

Astria Therapeutics Price Performance

ATXS stock opened at $12.57 on Monday. Astria Therapeutics has a 1-year low of $3.56 and a 1-year high of $12.72. The business has a 50 day simple moving average of $9.98 and a two-hundred day simple moving average of $7.28. The company has a market capitalization of $717.56 million, a price-to-earnings ratio of -6.25 and a beta of 0.21.

Institutional Trading of Astria Therapeutics

Hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP lifted its holdings in shares of Astria Therapeutics by 9.6% in the 3rd quarter. Vestal Point Capital LP now owns 4,956,000 shares of the biotechnology company’s stock valued at $36,080,000 after acquiring an additional 434,000 shares during the last quarter. Millennium Management LLC increased its stake in Astria Therapeutics by 2.2% during the third quarter. Millennium Management LLC now owns 3,034,527 shares of the biotechnology company’s stock worth $22,091,000 after acquiring an additional 64,800 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in Astria Therapeutics during the third quarter valued at approximately $98,000. Raymond James Financial Inc. raised its position in Astria Therapeutics by 6.0% during the third quarter. Raymond James Financial Inc. now owns 96,020 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 5,437 shares during the period. Finally, Brooklyn Investment Group lifted its stake in shares of Astria Therapeutics by 204.4% in the 3rd quarter. Brooklyn Investment Group now owns 34,833 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 23,389 shares during the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.